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Owen Bowden-Jones, John Dunn, Anthony Glasper, Emily Finch, John Strang
Summary
Background Poor adherence to treatment diminishes its individual and public health benefi t. Financial incentives, 
provided on the condition of treatment attendance, could address this problem. Injecting drug users are a high-risk 
group for hepatitis B virus (HBV) infection and transmission, but adherence to vaccination programmes is poor. We 
aimed to assess whether contingency management delivered in routine clinical practice increased the completion of 
HBV vaccination in individuals receiving opioid substitution therapy.
Methods In our cluster randomised controlled trial, we enrolled participants at 12 National Health Service drug 
treatment services in the UK that provided opioid substitution therapy and nurse-led HBV vaccination with a super-
accelerated schedule (vaccination days 0, 7, and 21). Clusters were randomly allocated 1:1:1 to provide vaccination 
without incentive (treatment as usual), with fi xed value contingency management (three £10 vouchers), or escalating 
value contingency management (£5, £10, and £15 vouchers). Both contingency management schedules rewarded 
on-time attendance at appointments. The primary outcome was completion of clinically appropriate HBV vaccination 
within 28 days. We also did sensitivity analyses that examined vaccination completion with full adherence to 
appointment times and within a 3 month window. The trial is registered with Current Controlled Trials, number 
ISRCTN72794493.
Findings Between March 16, 2011, and April 26, 2012, we enrolled 210 eligible participants. Compared with six (9%) of 
67 participants treated as usual, 35 (45%) of 78 participants in the fi xed value contingency management group met 
the primary outcome measure (odds ratio 12·1, 95% CI 3·7–39·9; p<0·0001), as did 32 (49%) of 65 participants in the 
escalating value contingency management group (14·0, 4·2–46·2; p<0·0001). These diff erences remained signifi cant 
with sensitivity analyses.
Interpretation Modest fi nancial incentives delivered in routine clinical practice signifi cantly improve adherence to, 
and completion of, HBV vaccination programmes in patients receiving opioid substitution therapy. Achievement of 
this improvement in routine clinical practice should now prompt actual implementation. Drug treatment providers 
should employ contingency management to promote adherence to vaccination programmes. The eff ectiveness of 
routine use of contingency management to achieve long-term behaviour change remains unknown.
Funding National Institute for Health Research (RP-PG-0707-10149).
Copyright © Weaver et al. Open Access article distributed under the terms of CC BY.
Introduction
Poor adherence to treatment is a widespread problem 
that reduces the individual and public benefi t from 
numerous health interventions.1 For addiction, evidence-
based treatments exist (eg, opioid substitution 
treatment),2 but do not provide their full benefi t because 
of poor adherence and high progressive dropout.3 
Building on the behavioural principles of operant 
conditioning, contingency manage ment involves the 
systematic application of positive reinforcement4 (use of 
fi nancial or material incentives) to promote adherence to 
treatment or behaviour consistent with treatment goals 
and thereby amplify the benefi ts of existing treatment. 
Substantial interest exists in the application of 
contingency management as an adjunct to treatments 
delivered in various contexts,4 and particularly within 
treatment for addictions.5
Strong evidence from the USA supports the 
eff ectiveness of contingency management to improve 
outcomes of existing addiction treatments.6 However, the 
generalisability of these fi ndings might be restricted by 
the extensive use of specialist therapists employed solely 
to deliver contingency management, and its frequent 
assessment within specialist research centres. The UK 
National Institute for Health and Care Excellence (NICE) 
recommends that contingency management should be 
applied and assessed in routine clinical practice in the 
UK,7,8 and identifi es adherence to time-limited health 
interventions such as hepatitis B virus (HBV) 
vaccination9,10 as a potential intervention target. However, 
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despite international evidence for contingency 
management, in common with most other developed 
and developing health-care systems, the UK has no track 
record in this area. Hence the feasibility, acceptability, 
and clinical and cost-eff ectiveness of this intervention 
need to be assessed in routine drug-treatment settings.11
HBV infection (and associated health sequelae) is a 
global health problem.12 Injecting drug users are a major 
risk group for infection and transmission13 and an 
important target population for vaccination.14 In the UK, 
HBV infection aff ects about 22% of injecting drug users.15 
Clinical guidance recommends routine HBV vaccination 
be off ered to people receiving addiction treatment,16 but 
although prison-based programmes have improved 
vaccination uptake in recent years,17 a need remains to 
improve the uptake and completion of vaccination 
programmes off ered to people entering community 
treatment.18 We aimed to assess the eff ectiveness of 
contingency management in promoting the completion of 
HBV vaccination in community drug-treatment settings, 
comparing the off er of fi xed and escalating incentives for 
on-time attendance at vaccinations with the off er of 
vaccination without incentive.
Methods
Study design and participants
In our cluster randomised trial, we enrolled participants at 
12 National Health Service drug treatment clinics in the 
UK. All sites provided opioid substitution therapy and 
nurse-led blood-borne virus services. We trained clinic 
staff  to deliver contingency management as part of routine 
care. In accordance with clinical guidelines, all sites off ered 
HBV vaccination to patients starting new treatment 
episodes according to a super-accelerated vaccination 
schedule (three injections on days 0, 7 and 21).16,19
Local clinical teams assessed eligibility of patients in 
participating services within the fi rst 2 months of a new 
period of opioid substitution therapy. Adults aged 
18–65 years were eligible if they had previous, current, or 
future risk of injecting drug use and agreed to receive 
vaccination, participate in the trial, and provided written 
informed consent. Individuals were excluded if they were 
pregnant or breastfeeding or not clinically eligible to 
receive HBV vaccination (ie, previously received 
vaccination or had HBV infection).
The trial was reviewed by the North London Research 
Ethics Committee 2 and received a favourable ethical 
opinion on Sept 27, 2010 (reference 10/H0724/56). 
Randomisation and masking
Randomisation was undertaken independently by the 
Kings Clinical Trials Unit (Institute of Psychiatry, King’s 
College London, London, UK). Clusters were assigned to 
treatments with a random permuted blocks approach, with 
a block size of 3 in a 1:1:1 allocation ratio. Sites were 
randomly allocated to provide HBV vaccination without 
contingency management (treatment-as-usual group), 
HBV vaccination with fi xed-value incentive (fi xed group; 
service users received up to an aggregate total of £30, 
provided as a £10 voucher at each of three vaccinations), or 
HBV vaccination with contingency management of an 
incentive that increased in value (escalating group; 
participants received up to an aggregate total of £30 in 
vouchers, provided as a £5 voucher at fi rst vaccination visit, 
a £10 voucher at second vaccination visit, and a £15 voucher 
at third vaccination visit). In both contingency management 
groups, eligibility to receive a voucher was conditional on 
attendance at the appointment on time and compliance 
with the vaccination schedule as clinically indicated.
In most sites, vaccination was off ered to all patients 
whose clinical eligibility was established through a verbal 
assessment. However, some sites used blood tests to 
establish a patient’s HBV antibody concentrations either 
before or during the vaccination schedule. Where this 
practice was followed, if the blood test showed the patient 
had suffi  ciently high concentrations of antibodies, the 
service would either not start the vaccination schedule or 
would not continue with the vaccination schedule if it had 
been started. Because of the potential eff ect of this 
diff erence in practice on our primary outcome, 
randomisation was stratifi ed by whether sites undertook 
blood tests and acted upon the results within 7 days of the 
fi rst vaccination appointment (ie, before vaccination 2). 
Three of 12 sites undertook blood testing. An open-label 
design was used for this trial owing to the nature of the 
intervention; researchers, clinicians, and statistician were 
unmasked to treatment allocation.
Procedures
The vaccination schedule off ered in each site was identical 
apart from the absence or presence (and type) of fi nancial 
incentive. We used a super-accelerated vaccination 
schedule in accordance with best clinical practice as 
recommended by the UK Department of Health16,19 for use 
with injecting drug users or individuals at risk of injecting. 
These individuals are at high risk of contraction and 
transmission of the disease and should be immunised as 
rapidly as possible. 
Patients completed a research interview before 
enrolment into the trial. The research interview assessed 
sociodemographic variables, drug and alcohol use, and 
drug treatment history (Opiate Treatment Index20 and 
Alcohol Use Disorders Identifi cation Test21) and health 
status (EQ-5D22 and Short Form-3623). On conclusion of 
the interview, site treatment allocation was revealed and 
when relevant, scripted information was provided 
explaining eligibility for receipt of the fi nancial incentives. 
Patients were given a fi rst vaccination appointment 
(day 0) at least 24 h after enrolment. Attendance at the 
three HBV vaccination appointments was recorded for up 
to 3 months.
Nurses providing HBV vaccinations received training 
on trial procedures and, if working in an intervention 
site, the principles and practice of contingency 
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management (panel 1).5 All trial appointments were 
recorded as audio and a random sample of 40 recordings 
(stratifi ed by treatment allocation and fi rst or subsequent 
vaccination) were rated for adherence to the intervention 
protocol according to a bespoke measurement scale. We 
regarded good adherence as a score of at least 66% and 
poor adherence as a score of less than 33%. 
Outcomes
The primary outcome was the completion of HBV 
vaccination within 28 days of the fi rst vaccination (day 0). 
Patients were defi ned as completers if they attended all 
scheduled, clinically relevant vaccination appointments, or 
attended but were not vaccinated because of existing 
immunity. We chose 28 days as the primary endpoint 
because this timeframe was consistent with some 
rescheduling of appointments by patients (permitted by 
our protocol if agreed in advance) and the occasional 
necessary rescheduling of appointments by clinics. 
Sensitivity analyses examined completion of the vaccination 
schedule with a strict defi nition of completer requiring on-
time attendance at all relevant vaccination appointments, 
and a more relaxed defi nition requiring patients to complete 
all relevant vaccination appointments within 3 months.
We also recorded incidence of serious adverse events, 
which we assessed for seriousness and relatedness to 
vaccination.
Statistical analysis
We calculated the sample size to allow a separate 
comparison of treatment as usual versus fi xed and 
escalating contingency management approaches. No 
directly comparable data exist from which to base a 
power calculation, but we used data from a similar 
study9 that compared contingency management with an 
outreach programme promoting completion of HBV 
vaccination that reported large diff erences (69% for the 
CM approach vs 23% for the outreach programme). The 
sample size was based on the assumption that the 
percentage of participants completing clinically relevant 
vaccination would increase from 23% in the treatment 
as usual conditions to 69% in the two contingency 
management conditions.
A randomised controlled trial would require an overall 
sample size of 29 participants per group to provide 90% 
power for a two-sided test at 5% signifi cance to detect a 
diff erence of completers of 69% in contingency 
management and 23% in treatment as usual (allowing 
5% attrition). To account for possible cluster eff ects, we 
increased the sample size by an infl ation factor of 1·75, 
calculated on assumption of intraclass correlation of 
0·05 on the basis of previous studies24 with a planned 
16 participants per cluster. This increase equated to 
51 participants per intervention group, with at least three 
clusters per intervention needed to achieve 90% power. 
We therefore planned to trial each intervention in four 
clusters, with 16 participants per cluster (192 participants 
overall, 64 participants per trial intervention, and 
12 clusters) because recruitment of 192 participants 
provides 90% power for a two-sided test at 5% signifi cance 
between each contingency management treatment 
versus treatment as usual. The study was also powered 
suffi  ciently if the trial resulted in unequal cluster sizes 
based on an average of 16 per site with minimum cluster 
size of six and maximum of 26.25
The statistical analysis plan was approved by the trial 
steering and data monitoring committees. We regarded 
p<0·05 as signifi cant for all analyses. We analysed all 
data at the individual level, accounting for clustering at 
the site level and based on the intention-to-treat sample. 
We summarised continuous variables as mean (SD) and 
categorical variables as n (%). The unadjusted comparison 
of categorical variables was by Fisher’s exact test. Our 
primary outcome analysis measured on-time attendance 
for vaccination and did not depend on post-intervention 
follow-up of the patient. Therefore, attrition contributed 
to our outcome measure and thus no outcome data 
would be regarded as missing.
For the primary analysis, we assessed the binary outcome 
completer status with a generalised estimating equation 
(GEE) to account for potential correlations of outcomes 
within sites, specifying an exchangeable correlation matrix. 
We adjusted the GEE logistic regression (specifying a 
binomial family and logit link) for trial group and the 
randomisation stratifi cation factor (blood test) with a fi xed-
eff ects approach.26 We also calculated the number needed 
to treat (NNT) to achieve completer status.
In the sensitivity analyses, we recategorised data into 
the outcome completer status, adjusted for the two time 
assumptions. We analysed the binary outcomes within a 
GEE, specifying an exchangeable correlation matrix and 
adjusting the GEE logistic regression (with a binomial 
family and logit link) for trial group and the randomisation 
stratifi cation factor with a fi xed-eff ects approach. We 
Panel 1: Training and supervision of nurses
All staff  delivering hepatitis B virus (HBV) vaccination with or without contingency 
management were registered nurses working within substance misuse services and 
employed as either keyworkers (providing HBV vaccinations as part of their role) or specialist 
nurses providing a range of blood-borne virus interventions (including HBV vaccinations). 
All nurses had previously received training in provision of HBV vaccinations.
Nurses responsible for provision of HBV vaccinations were instructed on trial procedures 
and those working in sites allocated to contingency management also received a bespoke 
1 day training course in the principles and practice of contingency management, 
including simulation and role play from psychologists on the research team. A training 
manual was written by the research team and provided to all nurses.
All HBV vaccination appointments were recorded as audio. Supervision (either face-to-face 
or telephone) was provided to nurses working in sites allocated to contingency management 
throughout the trial by a psychologist from the research team after review of selected audio 
recordings. 40 audio recordings were reviewed and rated for adherence to the contingency 
management protocol by use of a specifi cally developed adherence measure.
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Treatment as usual 
(n=67)
Fixed value contingency 
management (n=78)
Escalating value contingency 
management (n=65)
Overall
(N=210)
Age, years 37·7 (8·6, 18–59) 35·5 (8·1, 21–51) 35·5 (7·9, 18–55) 36·2 (8·2, 18–59)
Sex
Male 51 (76%) 66 (85%) 50 (77%) 167 (80%)
Female 16 (24%) 12 (15%) 15 (23%) 43 (20%)
Ethnicity
White 51 (76%) 62 (79%) 45 (69%) 158 (75%)
Black 4 (6%) 1 (1%) 1 (2%) 6 (3%)
Asian 2 (3%) 11 (14%) 14 (22%) 27 (13%)
Other 10 (15%) 4 (5%) 5 (8%) 19 (9%)
Employment
Unemployed 61 (91%) 69 (88%) 53 (82%) 183 (87%)
Employed or student 6 (9%) 9 (12%) 10 (15%) 25 (12%)
Other 0 0 2 (3%) 2 (1%)
Normal living arrangement
With partner or spouse 9 (13%) 12 (15%) 15 (23%) 36 (17%)
With friends 8 (12%) 3 (4%) 5 (8%) 16 (8%)
Alone 28 (42%) 35 (45%) 31 (48%) 94 (45%)
Other 22 (33%) 28 (36%) 14 (22%) 64 (30%)
(Table 1 continues on next page)
Figure 1: Trial profi le
HBV=hepatitis B virus. *Site undertook blood testing for HBV. 
12 clinics randomly allocated
273 individuals assessed for eligibility 272 individuals assessed for eligibility369 individuals assessed for eligibility
67 available for analyses 65 available for analyses78 available for analyses
4 clinics allocated to provide 
 treatment as usual
4 clinics allocated to provide escalating 
 value contingency management
4 clinics allocated to provide fixed
 value contingency management
291 excluded
 2 not aged 18–65 years
 59 opiate drug use outside of 2 
  month window
 8 not current or previous opiate 
  drug user
 1 pregnant or breastfeeding
 143 received previous course of HBV
  vaccine
 9 self-reported current or previous 
  HBV infection
 4 full screening data not available
 11 did not attend baseline 
  assessment
 1 not asked to consent
 43 not willing to receive HBV 
  vaccination
 9 not willing to participate
 1 not willing to give consent
207 excluded
 12 opiate drug use outside of 2 
  month window
 15 not current or previous opiate 
  drug user
 5 pregnant or breastfeeding
 130 received previous course of HBV
  vaccine
 3 self-reported current or previous 
  HBV infection
 4 did not attend baseline 
  assessment
 2 not asked to consent
 18 not willing to receive HBV 
  vaccination
 17 not willing to participate
 1 not willing to give consent
206 excluded
 1 not aged 18–65 years
 62 opiate drug use outside of 2 
  month window
 3 not current or previous opiate 
  drug user
 9 pregnant or breastfeeding
 103 received previous course of HBV
  vaccine
 8 self-reported current or previous 
  HBV infection
 4 did not attend baseline 
  assessment
 3 not asked to consent
 5 not willing to receive HBV 
  vaccination
 8 not willing to participate
67 eligible participants enrolled
 17 at control site A
 11 at control site B
 20 at control site C*
 19 at control site D
65 eligible participants enrolled
 18 at escalating group site A
 11 at escalating group site B
 20 at escalating group site C
 16 at escalating group site D*
78 eligible participants enrolled
 20 at fixed group site A
 20 at fixed group site B
 20 at fixed group site C
 18 at fixed group site D*
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checked model assumptions by use of diagnostic plots. 
All analyses were done in Stata version 11.2. 
The trial is registered, number ISRCTN72794493.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had fi nal 
responsibility for the decision to submit for publication.
Results
Between Feb 1, 2011, and Jan 31, 2012, we randomly 
allocated 12 services (clusters) to three treatment groups 
(fi gure 1). 210 (23%) of 914 patients screened for eligibility 
consented to enrolment (fi gure 1). Study participants 
were broadly representative of patients entering opioid 
substitution therapy in the UK,27 in that they were mostly 
men (167 [80%] participants) and white (158 [75%] 
participants) with a mean age of 36·2 years (SD 8·2). The 
three study groups were well matched on key 
Treatment as usual 
(n=67)
Fixed value contingency 
management (n=78)
Escalating value contingency 
management (n=65)
Overall
(N=210)
(Continued from previous page)
Accommodation
Owner occupied 2 (3%) 8 (10%) 1 (2%) 11 (5%)
Rented private 10 (15%) 18 (23%) 19 (29%) 47 (22%)
Rented (LA, HA) 30 (45%) 16 (21%) 26 (40%) 72 (34%)
Living with relatives 0 8 (10%) 9 (14%) 17 (8%)
Bed and breakfast or hotel 2 (3%) 1 (1%) 2 (3%) 5 (2%)
Hostel 12 (18%) 9 (12%) 1 (2%) 21 (10%)
NFA 9 (13%) 11 (14%) 6 (9%) 26 (12%)
Other 2 (3%) 8 (10%) 1 (2%) 11 (5%)
Prison history
Ever imprisoned (sentenced or remand) 47 (70%) 41 (53%) 26 (40%) 106 (50%)
Ever been in prison (on remand) 41 (61%) 32 (41%) 18 (28%) 91 (43%)
Ever been in prison (sentenced) 39 (58%) 39 (50%) 25 (38%) 103 (49%)
Off ered hepatitis B vaccination in prison 24 (36%) 18 (23%) 7 (11%) 49 (23%)
Health status
EuroQOL (VAS score 0–100) 50·0 (20·5, 0–90) 52·2 (22·4, 0–96) 55·2 (21·4, 10–95) 52·4 (21·5, 0–96)
SF-36 mental health component (0–100) 46·0 (10·5, 20–67) 46·1 (11·8, 16–69) 46·1 (11·3, 13–66) 46·1 (11·2, 13–69)
SF-36 physical health component (0–100) 28·6 (14·4, 2–60) 30·0 (14·8, 4–62) 32·1 (14·4, 4–64) 30·2 (14·6, 2–64)
Drug use
Age of fi rst opiate use, years 23·5 (9·1, 12–51) 21·7 (7·8, 12–45) 23·9 (7·9, 12–51) 22·9 (8·3, 12–51)
Age of regular opiate use, years 25·1 (8·8, 13–51) 24·2 (7·9, 12–46) 26·1 (7·8, 14–51) 25·1 (8·2, 12–51)
Age fi rst injected, years 26·4 (7·8, 12–49) 25·1 (7·3, 12–45) 24·7 (6·5, 16–41) 25·5 (7·2, 12–49)
Age fi rst received help, years 30·7 (8·8, 17–54) 29·3 (8·4, 13–49) 30·4 (8·3, 17–54) 30·1 (8·5, 13–54)
Times in opiate treatment 2·9 (3·5, 0–20) 2·2 (3·1, 0–20) 1·8 (2·5, 0–10) 2·3 (3·1, 0–20)
Alcohol use
AUDIT score (0–40) 12·2 (11·9, 0–36) 10·4 (11·5, 0–37) 7·5 (9·2, 0–37) 10·1 (11·1, 0–37)
AUDIT score <8 (non-harmful use) 31 (46%) 45 (58%) 44 (68%) 120 (57%)
AUDIT score 8–15 (problem use, medium) 15 (22%) 11 (14%) 10 (15%) 36 (17%)
AUDIT score 16–<20 (problem use, high) 4 (6%) 5 (6%) 4 (6%) 13 (6%)
AUDIT score ≥20 (possible dependency) 17 (25%) 17 (22%) 7 (11%) 41 (20%)
Drug use in previous 30 days
Heroin 51 (76%) 72 (92%) 54 (83%) 177 (84%)
Crack 45 (67%) 44 (56%) 32 (49%) 121 (58%)
Cocaine 8 (12%) 9 (12%) 5 (8%) 22 (10%)
Bezodiazapines 16 (24%) 28 (36%) 14 (22%) 58 (28%)
Amphetamines 2 (3%) 4 (5%) 2 (3%) 8 (4%)
Cannabis 35 (52%) 30 (38%) 28 (43%) 93 (44%)
Data are mean (SD, range) or n (%). LA=local authority. HA=housing association. NFA=no fi xed abode. VAS=visual analogue scale. SF-36=Short Form-36. AUDIT=alcohol use 
disorders identifi cation test.
Table 1: Baseline characteristics
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sociodemographic and health variables and previous drug 
use and treatments received (table 1).
About half of the participants treated as usual attended 
their fi rst vaccination appointment compared with about 
three-quarters of those receiving contingency management 
(table 2). At the second appointment, about a third of 
participants in the treatment as usual group attended 
compared with nearly two-thirds in the contingency 
management groups (table 2). At the third vaccination 
appointment, only a fi fth of patients in the treatment as 
usual group attended compared with half of participants in 
the contingency management groups (table 2).
Figures 2 and 3 show the proportions of the expected 
attendees who did attend (ie, individuals off ered each 
successive vaccination as opposed to the total enrolled 
population), showing the increased attrition in the 
treatment as usual group at all timepoints. The highest 
rate of attrition in all treatment groups occurred at the 
fi rst vaccination and attrition in the control group was 
higher than in both contingency management conditions 
at vaccinations 2 and 3 even in patients who attended 
vaccination 1 in the absence of reinforcement (fi gure 3).
Of participants in the contingency management 
groups who attended vaccinations, at least 80% did so on 
time and received clinically appropriate vaccinations at 
each of the three appointments (ie, achieved the target 
behaviour; table 2). By contrast, only 50–65% of the 
lower overall numbers of participants in the treatment 
as usual group who attended appointments did so on 
time (table 2).
Most attendances resulted in vaccination. 13 participants 
attended appointments but did not have a clinical need for 
(further) vaccination because they were identifi ed as 
having immunity (three in the treatment-as-usual group, 
four in the fi xed contingency management group, and six 
in the escalating contingency management group). All 
were regarded as completers in our outcome analyses. 
Four participants attended but refused vaccination (two in 
Vaccination 1 (day 0)* Vaccination 2 (day 7) Vaccination 3 (day 21)
Treatment 
as usual 
(n=67)
Fixed
(n=78)
Escalating 
(n=65)
Total
(n=210)
Treatment 
as usual 
(n=67)
Fixed
(n=78)
Escalating 
(n=65)
Total
(n=210)
Treatment 
as usual 
(n=67)
Fixed 
(n=78)
Escalating 
(n=65)
Total 
(n=210)
Attendance
Enrolled and expected to attend 67
(100%)
78 
(100%)
65 
(100%)
210 
(100%)
31
(46%)
58 
(74%)
47
(72%)
136 
(65%)
22
(33%)
46
(59%)
39
(60%)
107 
(51%)
Attended 34
(51%)
60
(77%)
49
(75%)
143 
(68%)
23
(34%)
50 
(64%)
42
(65%)
115
(55%)
14
(21%)
37
(47%)
33
(51%)
84 
(40%)
Did not attend 33
(49%)
18
(23%)
16
(25%)
67
(32%)
8
(12%)
8
(10%)
5
(8%)
21
(10%)
8
(12%)
9
(12%)
6
(9%)
23 
(11%)
Compliance with appointment time
Attended scheduled appointment on time† 21/34 
(62%)
52/60 
(87%)
45/49 
(92%)
118/143 
(83%)
15/23
(65%)
46/50 
(92%)
38/42 
(90%)
99/115 
(86%)
7/14 
(50%)
32/37 
(86%)
32/33 
(97%)
71/84 
(85%)
Attended, but not scheduled appointment 
date or time‡
13/34 
(38%)
8/60 
(13%)
4/49
(8%)
25/143 
(17%)
8/23
(35%)
4/50 
(8%)
4/42 
(10%)
16/115 
(14%)
7/14 
(50%)
5/37 
(14%)
1/33
(3%)
13/84 
(15%)
Compliance with vaccination
Vaccinated 30/34 
(88%)
56/60 
(93%)
46/49 
(94%)
132/143 
(92%)
20/23
(87%)
45/50 
(90%)
39/42 
(93%)
104/115 
(90%)
14/14 
(100%)
37/37 
(100%) 
32/33 
(97%)
83/84 
(99%)
Not vaccinated (immunity established) 3/34
(9%)
1/60
(2%)
2/49
(4%)
6/143 
(4%)
0/23 3/50 
(6%)
3/42
(7%)
6/115 
(5%)
0/14 0/37 1/33
(3%)
1/84 
(1%)
Not vaccinated (other valid clinical reason) 0/34 1/60
(2%)
1/49
(2%)
2/143 
(1%)
2/23
(9%)
2/50 
(4%)
0/42 4/115 
(3%)
·· ·· ·· ··
Not vaccinated (refused) 1/34
(3%)
2/60
(3%)
0/49 3/143 
(2%)
1/23
(4%)
0/50 0/42 1/115 
(1%)
·· ·· ·· ··
Achievement of target behaviours and reinforcement protocol fi delity
Achieved target behaviour (on time and 
vaccination and immunity established)§
21/34 
(62%)
49/60 
(82%)
44/49
(90%)
113/143 
(79%)
13/23
(57%)
44/50 
(88%)
38/42 
(90%)
95/115 
(83%)
7/14 
(50%)
32/37 
(86%)
32/33 
(97%)
71/84 
(85%)
Did not achieve target behaviour (non-
compliant with appointment schedule)¶
13/34 
(38%)
11/60 
(18%)
6/49
(12%)
30/143 
(21%)
10/23
(43%)
6/50 
(12%)
4/42 
(10%)
20/115 
(17%)
7/14 
(50%)
5/37 
(14%)
1/33
(3%)
13/84 
(15%)
Data are n (%) or n/n (%). *For vaccination 1 the base date (day 0) was defi ned as the fi rst appointment date off ered to the participant unless rescheduled by the clinic or the participant (but only in advance and 
with the agreement of the nurse); under these circumstances, the rescheduled appointment was regarded as day 0. Thus, any vaccinations given after day 0 will have been given because the patient did not 
attend the fi rst appointment off ered and then received the vaccination at a later date. †Participants who attended the vaccination appointment on the scheduled date and time, including those who attended at 
a date and time rescheduled by the client in advance and with the agreement of the clinic. ‡Participants who attended on the appointment date but outside the appointed timeframe, or on a rescheduled date 
made after a previous non-attendance of one or more appointments. §Participants who achieved target behaviour (ie, attended the appointment on time and either received the vaccination or were not 
vaccinated because they had established immunity). ¶Participants non-compliant with appointment schedule required to receive vaccination describes participants who attended but were not on-time, refused 
vaccination, or were required to attend on a subsequent day (eg, for clinical reasons) and did not do so.
Table 2: Participant fl ow through the vaccination schedule
Articles
www.thelancet.com   Vol 384   July 12, 2014 159
the treatment as usual group, two in the fi xed contingency 
management group).
Incentives were given in error when the target behaviour 
was not achieved in ten (4%) of 271 appointments in the 
contingency management groups. These errors mostly 
occurred when participants received a vaccination but had 
not attended on time. However, adherence, expressed as a 
mean percentage of the total adherence score was modest 
at 53%. Of the 40 audio recordings assessed, 13 (33%) were 
rated as good adherence and 13 (33%) were rated as poor 
adherence. Poor adherence scores were mainly due to 
failure to explain the schedule, off er suffi  cient praise, or 
check that participants understood the schedule. Tapes 
were independently rated by two reviewers and good inter-
rater reliability was achieved (intraclass correlation 0·873, 
95% CI 0·773−0·930).
Table 3 shows the proportion of participants in each 
group who completed the vaccination schedule in 28 days, 
the number of participants classifi ed as completers who 
were identifi ed as immune and received  up to three 
vaccinations (three in the treatment-as-usual group, four 
in the fi xed contingency management group, and fi ve in 
the escalating contingency management group), and the 
results of the GEE modelling.
In the primary outcome analysis, we noted 
signifi cantly increased completion rates for HBV 
vaccination in both contingency management groups 
compared with treatment as usual (table 3). Participants 
in both contingency management groups were more 
likely to complete the vaccination schedule within 
28 days than were those in the treatment as usual 
condition (table 3). The intraclass correlation coeffi  cient 
for the site clustering was estimated at 0·097.
Figure 2 shows the predictive probability from the 
fully adjusted GEE modelling of completion of 
vaccination within each group and confi rms that the 
diff erences in vaccination completion rates were 
signifi cant. Unadjusted χ² statistics show diff erences in 
the completion rates between the fi xed contingency 
management group and the treatment as usual group 
(35 of 78 in the fi xed group vs six of 67 in the treatment 
as usual group; χ² 22·9, p<0·0001) and escalating 
contingency management and treatment as usual 
(32 of 65 participants in the escalating group vs 
six of 67 participants in the treatment as usual group; 
χ² 26·1, p<0·0001).
Compared with treatment as usual, the NNT was 2·78 
(2·05–4·36) for fi xed contingency management and 
2·48 (95% CI 1·84–3·80) for escalating contingency 
management.
Our fi rst sensitivity analyses assessed whether 
contingency management was associated with increased 
full compliance with the vaccination schedule, through 
comparison of the proportions of participants who 
completed their vaccinations with the strict defi nition of 
completer that required on-time attendance at all 
relevant vaccination appointments. This measure might 
thus be regarded as a proxy for improved clinic 
effi  ciency. We noted substantially improved rates of 
completion for both contingency management groups 
versus treatment as usual (table 3, fi gure 2)
Our second sensitivity analysis assessed whether the 
benefi t of contingency management remained if a 
longer follow-up period was used, through comparison 
of the proportions of participants who completed their 
vaccinations with a relaxed defi nition of completer that 
required participants to complete all relevant vaccination 
appointments within 3 months of recruitment. In this 
analysis, completion rates were higher in all treatment 
groups, with the proportion of completers in the 
treatment as usual group increasing to 25% 
(17 of 67 participants). However, completion rates 
Figure 3: Predictive margins for the primary and sensitivity analyses 
(A) Completers of hepatitis B vaccination within 28 days (primary outcome). (B) Completers of hepatitis B 
vaccination attending all relevant appointments on time. (C) Completers of hepatitis B vaccination within 
3 months. Predictive margins (95% CIs) are derived from fully adjusted generalised estimating equation model, 
controlling for the blood test status and allowing for site at the cluster level.
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remained highest in the contingency management 
groups (table 3).
Three participants died in the treatment as usual group 
(one cardiac arrest, one deep vein thrombosis, and one 
unknown cause in a patient not administered vaccine). 
Other serious adverse events were one case of pneumonia 
in the treatment as usual group and one psychiatric 
admission in a participant in the fi xed contingency 
management group. No other serious adverse events were 
reported, and none was regarded as related to treatment. 
We noted no association between serious adverse events 
and trial condition (Fisher’s exact test p=0·50).
Discussion
NICE has identifi ed contingency management as a 
behavioural intervention with the potential to increase 
adherence to physical health interventions amongst drug 
users.7,8 In our study of HBV vaccination in routine clinical 
practice, we noted improved rates of completion of 
vaccination and adherence to appointment schedules 
when the off er of vaccination was combined with 
contingency management with fi nancial incentives 
(panel 2).
That incentives increase adherence is unremarkable, but 
the size of increase we noted was striking. The fi ndings of 
our health economic analysis are ongoing and will be 
presented elsewhere but, notably, increased vaccination 
was associated with relatively modest levels of fi nancial 
reinforcement. Our primary outcome measure was 
completion of the 21 day vaccination schedule within 
28 days. We noted a signifi cant advantage with each of the 
contingency management reinforcement conditions (49% 
and 45%) compared with treatment as usual (9%). In 
addition to the increased rate of completion, participants 
receiving contingency management mostly attend 
appointments on time, which off ers providers an 
additional advantage in terms of effi  cient use of resources.
In our primary analysis, the completion rate with 
treatment as usual was very low and merits comment. 
Ideally, we would be able to compare our fi ndings with 
data from routine practice. However, no information is 
available at present about vaccination completion rates as 
a proportion of patients off ered opioid substitution 
therapy or compliance with vaccination schedules. The 
completion rate in our treatment as usual group seems 
substantially worse than that recorded in injecting drug 
users in other settings (notably prison vaccination 
programmes),17 but comparison with data from such 
settings needs to be made with caution. The completion 
rate in our sensitivity analysis, which included 
vaccination up to 3 months, was substantially higher 
than it was in the primary analysis (25% vs 9%) and was 
close to the completion rates noted by Seal and colleagues 
(23%).9 This analysis probably provides a better 
comparison with routine completion rates. Nevertheless, 
even with this 3 month timeframe, the benefi t of 
contingency management over treatment as usual 
remained substantial, with completion rates exceeding 
50% in both contingency management groups.
Our study was not powered to examine diff erences 
between the two contingency management conditions 
but the gains achieved by each of the two schedules were 
much the same (odds ratio 12·1 and NNT of 2·78 for 
fi xed contingency management and odds ratio 13·9 for 
escalating contingency management and NNT of 2·48). 
Although clinician adherence to some aspects of the 
intervention protocol was modest (mainly failure to 
explain the schedule, off er suffi  cient praise, or check 
understanding of the participants), the incentive was 
given correctly in 261 (96%) of 271 appointments. One 
interpretation of these fi ndings is that these poorly 
delivered aspects of the protocol might be less powerful 
infl uences on outcome than the tangible fi nancial 
reinforcement which was invariably delivered 
appropriately. We are also mindful that, despite the high 
Treatment as 
usual (n=67)
Fixed value contingency 
management (n=78)
Escalating value 
contingency 
management (n=65)
Completers within 28 days (primary endpoint)
Completers (all) 6 (9%) 35 (45%) 32 (49%)
Completed 1 of 1 3 (4%) 1 (1%) 2 (3%)
Completed 2 of 2 0 3 (4%) 2 (3%)
Completed 3 of 3 3 (4%) 31 (40%) 28 (43%)*
Odds ratio† ·· 12·13 (7·37, 3·68–39·92; 
p<0·0001)
13·95 (8·53, 4·21–46·25; 
p<0·0001)
Completers attending all appointments on time (sensitivity analysis)
Completers (all) 5 (7%) 29 (37%) 32 (49%)
Completed 1 of 1 3 (4%) 1 (1%) 2 (3%)
Completed 2 of 2 0 2 (3%) 2 (3%)
Completed 3 of 3 2 (3%) 26 (33%) 28 (43%)*
Odds ratio† ·· 9·89 (4·80, 3·82–25·59; 
p<0·0001)
16·68 (8·61, 6·06–45·88; 
p<0·0001)
Completers within 3 months (sensitivity analysis)
Completers (all) 17 (25%) 41 (52%) 38 (58%)
Completed 1 of 1 3 (4%) 1 (1%) 2 (3%)
Completed 2 of 2 0 3 (4%) 3 (5%)
Completed 3 of 3 14 (21%) 37 (47%) 33 (51%)*
Odds ratio† ·· 3·38 (1·64, 1·30–8·76; 
p=0·012)
4·18 (2·32, 1·41–12·40; 
p=0·010)
Time to complete vaccination, days
First vaccination after day 0‡ 6·2 (14·2) 1·9 (5·1) 0·6 (3·1)
Second vaccination after day 0§ 25·3 (25·5) 11·0 (9·1) 9·5 (7·0)
Third vaccination after day 0§ 50·5 (24·5) 24·3 (7·8) 23·2 (5·7)
Data are n (%), odds ratio (SE, 95% CI; p value), or mean (SD). *Includes one participant whose immunity was 
established after receipt of the second vaccination; the participant attended vaccination 3 but was informed of their 
immunity status and not given a third vaccination. †From the fully adjusted generalised estimating equation model, 
controlling for the blood test status and allowing for site at the cluster level. ‡For vaccination 1 the base date (day 0) 
was defi ned as the fi rst appointment date off ered to the participant unless rescheduled by the clinic or the participant 
(but only in advance and with the agreement of the nurse); under these circumstances, the rescheduled appointment 
was regarded as day 0. Thus, any vaccinations given after day 0 will have been given because the patient did not attend 
the fi rst appointment off ered and then receiving the vaccination at a later date. §The base time was used for the 
calculation of the time to vaccination 2 and 3.
Table 3: Completers of hepatitis B vaccination schedule and outcome analysis
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odds ratios, only about half the participants completed 
the vaccination schedule in the contingency management 
groups. Elsewhere, we will present the results of 
secondary analyses in which clinician adherence, 
treatment fi delity, and competence to behavioural 
principles are included as predictors of outcome.
Our fi ndings suggests that contingency management for 
HBV vaccination is an eff ective and robust intervention—
irrespective of schedule—despite variation in staff 
adherence to some aspects of the reinforcement protocol. 
Three main conclusions can be drawn from our fi ndings. 
First, we identifi ed a powerful benefi cial eff ect of 
contingency management in relation to a time-limited 
physical health intervention, which nevertheless has 
enduring benefi t.36 Our fi ndings were obtained in real-
world clinical circumstances, and therefore support the 
conclusions of NICE7,8 that this adjunctive technique 
should be routinely applied to increase the individual 
and public benefi t of vaccination programmes in drug-
treatment settings. The low NNT and high odds ratios 
should attract the close attention of public health 
practitioners and clinicians working in the fi eld. These 
fi ndings might also have relevance to other areas of 
clinical practice in which clinical and public health 
benefi t could be achieved by incentivised improvement 
of treatment adherence in the short-term (eg, early 
antenatal care or tuberculosis testing).
Second, although diff erences in attrition at fi rst and 
subsequent vaccinations might attract some further 
debate and analysis, attrition was highest in the control 
arm at each vaccination. Our interpretation of these 
data is that (modest) reinforcement at each vaccination 
is probably necessary and prudent to achieve the 
clinically signifi cant health gains that are dependent on 
compliance with the full vaccination schedule. We 
would caution against too much further research focus 
on the precise schedule and instead we recommend 
concentrating energies on implementation.
Third, a strong case now exists for further rigorous 
assessment of contingency management in the UK for 
other areas of health-care provision. Investigators 
working in other clinical settings in which the patient 
and public health benefi t of current treatments would 
be enhanced by measures that improve compliance 
could benefi t from our fi ndings. Within the specialty of 
substance misuse, attention should now shift to more 
challenging areas of behaviour change (eg, reduction in 
illicit drug use),7,8 in which long-term robustness of the 
change is necessary for any health benefi t to be 
maintained.
Contributors
JS, TW and SP originally conceived the trial and secured research grant 
support. All authors made substantial contributions to the conception 
and design of the study, acquisition, or analysis of data, and writing 
and revision of the report. All authors were involved in interpretation 
of data and critical revision of the manuscript on behalf of the 
Contingency Management Programme team. JS was the principal 
investigator and guarantor of the study. TW was principal investigator 
Panel 2: Research in context
Systematic review
Evidence increasingly supports the eff ectiveness of 
contingency management for improvement of outcomes of 
drug users receiving substance misuse treatment. NICE7,8 
identifi es that contingency management can directly target 
the desired behaviour change (eg, drug abstinence) or can 
work synergistically by targeting intermediate behaviours 
(eg, attendance or medication adherence): two major 
meta-analyses report eff ectiveness of contingency 
management in reducing drug use.6,28 
Use of contingency management for time-limited 
interventions to produce irreversible health benefi ts 
(eg, hepatitis B virus [HBV] vaccination) was mooted by 
NICE7,8 but has received little attention in contingency 
management research; no meta-analysis has been 
published. Likewise for attention to physical comorbidities, 
apart from studies of contingency management to 
reinforce attendance for tuberculosis testing,29 adherence 
to tuberculosis medication,29–31 and to antiretroviral 
treatment for HIV.32 
In addition to small observational studies33,34 reporting 
increased uptake and completion of HBV vaccination 
associated with provision of fi nancial incentives to injecting 
drug users, there have been three randomised controlled 
trials examining contingency management targeted 
specifi cally at HBV vaccinations. One trial,9 despite modest 
sample size (n=96), found contingency management 
(monthly monetary incentives) was signifi cantly more 
eff ective than an outreach programme (weekly contact 
with outreach worker) in achieving completion of HBV 
vaccination within 6 months (69% vs 23%).9 A second trial10 
found contingency management (prize incentives) more 
successful than no contingency management with 
non-signifi cantly increased attendance of weekly sessions 
(82% vs 64%), increased compliance with all injections 
(77% vs 46%) and signifi cantly more injections received on 
the originally scheduled day (74% vs 51%).10 A third 
randomised controlled trial,35 from Australia, found 
monetary incentives (vouchers) more eff ective than no 
contingency management for completion of three-dose 
HBV vaccination (days 0, 7, 21) by injecting drug users. 
Monetary incentives not only improved compliance with 
HBV vaccination but also frequently achieved this within 
specifi ed appointment times.35
Interpretation
The fi ndings from our properly powered trial accord with 
previous studies, providing compelling evidence that 
contingency management signifi cantly improves completion 
of the three-injection vaccination schedule, so that 
approximately half of patients complete vaccination as 
scheduled. Further work is now required to refi ne the 
contingency management method to improve further the 
capture and completion of these vaccination schedules.
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